BioXcel creates subsidiary to develop cancer, neurology candidates
BioXcel Corp. (Branford, Conn.) launched new subsidiary BioXCel Therapeutics Inc. (BTI), which will use artificial intelligence-driven R&D to identify indications for candidates that demonstrated safety but not efficacy in Phase II testing or later.
BTI's pipeline includes BXCL701 -- an inhibitor of dipeptidyl peptidase-8 (DPP-9), DPP-9 and fibroblast activation protein (FAP) -- as both monotherapy and in combination with immune-checkpoint inhibitors to treat castration resistant prostate cancer (CRPC) and other cancers; and BXCL501, a sublingual formulation of an undisclosed FDA-approved anesthetic that selectively agonizes adrenergic receptor alpha 2a (ADRA2A), to treat acute agitation in schizophrenic and bipolar patients...
BCIQ Company Profiles